pharma · Cystic Fibrosis · Hepatitis C
Vertex Pharmaceuticals (Australia)
Vertex Pharmaceuticals (Australia) Pty.
Vertex Pharmaceuticals (Australia) is a pharma organization headquartered in Boston, USA. Primary therapeutic focus areas include Cystic Fibrosis, Hepatitis C, Pain, Chronic Hepatitis C, Acute Pain. NovaPharmaNews links
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
- Founded
- 1989
- Employees
- 6,304
- Programs
- 159
- Drugs
- 64
- Patents
- 991
Tezacaftor/Ivacaftor + Ivacaftor
Phase 2 · small molecule · Cystic Fibrosis
Tezacaftor/Ivacaftor + Ivacaftor for Cystic Fibrosis is a Phase 2 program (small_molecule) at Vertex Pharmaceuticals (Australia) Pty. with 1 ClinicalTrials.gov record(s).
Internal code 18RM039
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vertex Pharmaceuticals (Australia) Pty.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Cystic Fibrosis
- Status
- completed
- Trials
- 1